Metabolic Research Peptides · 30mg vial
Tirzepatide
Buy 3+, save 10% · Kit of 10, save 25%
Tirzepatide (LY3298176) is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It simultaneously activates both incretin pathways, producing complementary effects on insulin secretion, glucagon suppression, gastric emptying, and appetite signalling.
Research has investigated Tirzepatide extensively for its metabolic effects, including improvements in glycaemic control, body weight reduction, and lipid profiles. As a dual agonist, it combines the insulin-sensitizing and appetite-suppressing properties of GLP-1 with the additional metabolic benefits attributed to GIP receptor activation, representing a meaningful advance over single-agonist approaches in metabolic research.
Composition & Purity
Tirzepatide (LY3298176), Lyophilized powder
For research purposes only
Compound: Tirzepatide (LY3298176) — dual GIP/GLP-1 receptor agonist
Concentration: 30mg lyophilized powder
Purity: 99.77% (HPLC-UV/MS verified)
Storage: Refrigerate at 2–8°C. Protect from light. Reconstitute with bacteriostatic water prior to use.
Appearance: White lyophilized powder
- Size
- 30mg vial
- Weight
- 30mg
Composition & Purity
Tirzepatide (LY3298176), Lyophilized powder
- Laboratory
- Freedom Diagnostics
- Purity
- 99.77%
- Lot
- Y3L0P-1
- Report Date
- September 4, 2025
Third-party verified. Analysis performed by HPLC-UV/MS.
Suggested research dose: 2.5–15mg per administration. Gradual escalation protocol recommended. Consult published literature for specific parameters. For research purposes only.
For research purposes only. Not for human or veterinary use.